CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

监测（白血病特异性）免疫细胞在不同分期、治疗组以及疾病和治疗过程中的变化，有助于评估 AML 患者的抗白血病潜能和生存情况

英文原题：Monitoring of (Leukemia-Specific) Immune Cells in Stages, Treatment Groups and in the Course of Disease and Therapy Contributes to Qualify Antileukemic Potential and Survival in Patients with AML.

查看英文原题

Monitoring of (Leukemia-Specific) Immune Cells in Stages, Treatment Groups and in the Course of Disease and Therapy Contributes to Qualify Antileukemic Potential and Survival in Patients with AML.

PubMed 2025/10/23（内容时间） Int J Mol Sci Q1 · IF 5.6（JCR 2025）

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

技术：NK 细胞急性髓系白血病地区：欧洲
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

中文摘要

不同的AML治疗方案可能触发针对白血病细胞的不同免疫机制。不同免疫细胞亚群在介导抗白血病过程中的作用尚不清楚。在本研究中，我们使用流式细胞术纵向评估了17例AML患者在干细胞移植（SCT）前、病程中不同时间点以及疾病不同阶段的（白血病特异性）免疫亚型组成。

此外，我们将免疫细胞组成与患者对诱导治疗的反应及患者的中位生存期（本队列为3.8个月）进行了相关性分析。最后，我们比较了SCT前后患者的免疫细胞谱。（1）CR患者（与dgn和PD相比）的特征为白血病来源DC（DCleu）、（白血病特异性IFNg或TNFα产生或CD107a脱颗粒的）抗肿瘤相关T细胞（Tgd、Tβ7）、中央/效应记忆细胞（Tcm、Tem）频率较高，同时（白血病特异性）调节性T细胞频率较低。（2）具有较高频率（白血病特异性）抗肿瘤相关T细胞、（白血病特异性）记忆T细胞和NK细胞的患者表现出更长的中位生存时间和/或对诱导（RTI）治疗反应更好。（3）比较SCT前后患者，仅观察到微小差异。

然而，SCT前CR患者与SCT后CR患者相比，表现出更高频率的DC、Tcm、Tβ7和白血病特异性iNKT细胞。（1）免疫监测有助于在AML病程中不同阶段和不同治疗策略下量化（白血病特异性）免疫细胞。(2) 在“共刺激”（尤其是 KitM 诱导的）治疗后以及 CR 中，发现活化和抗肿瘤相关白血病特异性免疫细胞亚型的频率更高。(3) 特别是，DC/DCleu、（白血病特异性）抗肿瘤相关 T（记忆）细胞和 NK 细胞似乎在 CR 中占主导地位，并对 RTI 和生存产生积极影响。(4) 对（白血病特异性）免疫细胞亚型的监测有助于量化不同阶段和治疗组中个体 AML 患者的抗白血病潜力，也可用于预测患者的生存。

展开英文摘要原文

Various AML treatment regimens might trigger different immunological mechanisms against leukemic cells. The role of different immune cell subsets in the mediation of antileukemic processes is not clear. In this study, we longitudinally assessed (leukemia specific) immune subtype compositions in 17 AML patients before stem cell transplantation (SCT) at different timepoints in the course and in different stages of the disease using flow cytometry.

Further we correlated immune cell compositions with patients' response to induction therapy and the median survival (3. 8 months in our cohort) of the patients.

Finally, we compared immune cell profiles from patients before and after SCT. (1) Patients in CR (compared to dgn and PD) were characterized by higher frequencies of leukemia-derived DC (DCleu), (leukemia-specific-IFNg or TNFα producing or CD107a degranulating) anti-tumor relevant T cells (Tgd, Tβ7), central/effector memory cells (Tcm, Tem), alongside with lower frequencies of (leukemia-specific) regulatory T cells.

(2) Patients with higher frequencies of (leukemia-specific) antitumor relevant T cells, (leukemia-specific) memory T cells and NK cells demonstrated a prolonged median survival time and/or responded better to induction (RTI) treatment (3) Comparing patients before and after SCT, only minimal differences were observed.

However, patients in CR preSCT exhibited higher frequencies of DC, Tcm, Tβ7 and leukemia-specific iNKT cells compared to patients in CR postSCT . (1) Immune monitoring qualifies to quantify (leukemia-specific) immune cells in different stages and under different treatment strategies in the course of AML. (2) Higher frequencies of activating and antitumor relevant leukemia-specific immune cell subtypes found after 'costimulatory' (especially KitM induced) treatment' and in CR.

(3) In particular, DC/DCleu, (leukemia-specific) antitumor-relevant T (memory) and NK cells seem to dominate in CR and positively influence RTI and survival. (4) Monitoring of (leukemia-specific) immune cell subtypes contribute to quantify individual AML patients' antileukemic potential in different stages and treatment groups and also could be used to predict patients' survival.

论文信息

作者
Stein J、Anand P、Abdulmajid J、Hartz A、Unterfrauner M、Feng X、Schmieder N、Kruk L
单位
Department of Medicine III, University Hospital of Munich, Immunomodulation, Marchioninistr. 15, 81377 Munich, Germany.Germany
期刊
International journal of molecular sciences2025 Oct 23
原文标识
PubMed 41226377　·　DOI 10.3390/ijms262110336

在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →